Merck KGaA – German Innovation in Medicine and Science
Merck KGaA
Merck KGaA is a German science and technology company headquartered in Darmstadt. Its history goes back to 1668, when Friedrich Jacob Merck took over the Engel-Apotheke pharmacy in Darmstadt. About 70% of the capital is held by the family holding company E. Merck KG; the shares are listed on the Frankfurt Stock Exchange and are part of the DAX index.
The group has three business sectors: Healthcare, Life Science and Electronics. In the US and Canada it operates under the EMD name — its pharmaceutical business there is EMD Serono — because the Merck name in those countries belongs to the American company Merck & Co. The two are separate, unrelated companies.
The healthcare business focuses on oncology, neurology and immunology, fertility, and medicines for diabetes, thyroid and cardiovascular conditions. Its well-known products include Bavencio (avelumab) in oncology, Mavenclad (cladribine) and Rebif (interferon beta-1a) for multiple sclerosis, Gonal-f (follitropin alfa) in reproductive medicine, Glucophage (metformin), Concor (bisoprolol) and Euthyrox (levothyroxine).
Erbitux (cetuximab) is a monoclonal antibody against the epidermal growth factor receptor (EGFR), used in metastatic colorectal cancer and squamous cell carcinoma of the head and neck. It was developed by the US company ImClone Systems; Merck KGaA holds the rights worldwide outside North America.
Unifarm carries Merck KGaA's oncology medicine Erbitux 500 (cetuximab).